The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

A Simple Dosing Scheme for Intravenous Busulfan Based on Retrospective Population Pharmacokinetic Analysis in Korean Patients

  • Choe, Sang-Min (Department of Clinical Pharmacology & Therapeutics, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kim, Gayeong (Department of Clinical Pharmacology & Therapeutics, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Lim, Hyeong-Seok (Department of Clinical Pharmacology & Therapeutics, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Cho, Sang-Heon (Department of Clinical Pharmacology & Therapeutics, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Ghim, Jong-Lyul (Department of Clinical Pharmacology & Therapeutics, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Jung, Jin-Ah (Department of Clinical Pharmacology & Therapeutics, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kim, Un-Jib (Department of Clinical Pharmacology & Therapeutics, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Noh, Gyu-Jeong (Department of Clinical Pharmacology & Therapeutics, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Bae, Kyun-Seop (Department of Clinical Pharmacology & Therapeutics, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Lee, Dong-Ho (Department of Clinical Pharmacology & Therapeutics, University of Ulsan College of Medicine, Asan Medical Center)
  • Received : 2012.05.12
  • Accepted : 2012.07.06
  • Published : 2012.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

Busulfan is an antineoplastic agent with a narrow therapeutic window. A post-hoc population pharmacokinetic analysis of a prospective randomized trial for comparison of four-times daily versus once-daily intravenous busulfan was carried out to search for predictive factors of intravenous busulfan (iBu) pharmacokinetics (PK). In this study the population PK of iBu was characterized to provide suitable dosing recommendations. Patients were randomized to receive iBu, either as 0.8 mg/kg every 6 h or 3.2 mg/kg daily over 4 days prior to hematopoietic stem cell transplantation. In total, 295 busulfan concentrations were analyzed with NONMEM. Actual body weight and sex were significant covariates affecting the PK of iBu. Sixty patients were included in the study (all Korean; 23 women, 37 men; mean [SD] age, 36.5 [10.9] years; weight, 66.5 [11.3] kg). Population estimates for a typical patient weighing 65 kg were: clearance (CL) 7.6 l/h and volume of distribution (Vd) 32.2 l for men and 29.1 L for women. Inter-individual random variabilities of CL and $V_d$ were 16% and 9%. Based on a CL estimate from the final PK model, a simple dosage scheme to achieve the target $AUC_{0-inf}$ (defined as median AUC0-inf with a once-daily dosage) of 26.18 $mg/l{\cdot}hr$, was proposed: $24.79{\cdot}ABW^{0.5}mg$ q24h, where ABW represents the actual body weight in kilograms. The dosing scheme reduced the unexplained interindividual variabilities of CL and Vd of iBu with ABW being a significant covariate affecting clearance of iBU. We propose a new simple dosing scheme for iBu based only on ABW.

Keywords

References

  1. Schuler US, Ehrsam M, Schneider A, Schmidt H, Deeg J, Ehninger G. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant. 1998;22:241-244. https://doi.org/10.1038/sj.bmt.1701322
  2. Ehrsson H, Hassan M, Ehrnebo M, Beran M. Busulfan kinetics. Clin Pharmacol Ther. 1983;34:86-89. https://doi.org/10.1038/clpt.1983.134
  3. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, Tötterman T, Eksborg S, Simonsson B. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol. 1989;36:525-530. https://doi.org/10.1007/BF00558081
  4. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, Mcdonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055-3060.
  5. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20(4 Suppl 4):18-25.
  6. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225-230.
  7. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002;8:477-485. https://doi.org/10.1053/bbmt.2002.v8.pm12374452
  8. Drugs@FDA. [cited 2009 11 Sep]; Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=BUSULFEX.
  9. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, Totterman T, Eksborg S, Simonsson B. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol. 1989;36:525-530. https://doi.org/10.1007/BF00558081
  10. Hassan M, Oberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, Lönnerholm G, Smedmyr B, Taube A, Wallin I, et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol. 1991;28:130-134. https://doi.org/10.1007/BF00689702
  11. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, Santos GW, Colvin OM. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61. https://doi.org/10.1007/BF00694339
  12. Ryu SG, Lee JH, Choi SJ, Lee JH, Lee YS, Seol M, Hur EH, Lee SH, Bae KS, Noh GJ, Lee MS, Yun SC, Han SB, Lee KH. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13: 1095-1105. https://doi.org/10.1016/j.bbmt.2007.06.005
  13. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2:187-193. https://doi.org/10.1200/JCO.1984.2.3.187
  14. Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, Slattery JT. The impact of obesity and disease on busulfan oral clearance in adults. Blood. 1999;93:4436-4440.
  15. Devine D. Case study number 25 gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650-655.
  16. Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant. 2002;8:619-624. https://doi.org/10.1053/bbmt.2002.v8.abbmt080619
  17. Arand M, Muhlbauer R, Hengstler J, Jager E, Fuchs J, Winkler L, Oesch F. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem. 1996;236: 184-186. https://doi.org/10.1006/abio.1996.0153
  18. dos Reis EO, Vianna-Jorge R, Suarez-Kurtz G, Lima EL, Azevedo Dde A. Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19:1666-1674. https://doi.org/10.1002/rcm.1962
  19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41. https://doi.org/10.1159/000180580
  20. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
  21. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303-311.
  22. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr. 1978;93: 62-66. https://doi.org/10.1016/S0022-3476(78)80601-5
  23. Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep. 1970;54:225-235.
  24. Boyd E. The Growth of the Surface Area of the Human Body. London: University of Minnesota; 1935.
  25. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511-528. https://doi.org/10.1007/BF01061469
  26. Jonsson EN, Karlsson MO. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.
  27. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231-252. https://doi.org/10.1023/A:1011527125570
  28. Cook RD, Weisberg S. Residuals and Influence in Regression. New York: Chapman and Hall; 1982.
  29. Christensen R, Pearson LM, Johnson W. Case-Deletion diagnostics for mixed models. Technometrics. 1992;34:38-45. https://doi.org/10.2307/1269550
  30. Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol. 2006;57:191-198. https://doi.org/10.1007/s00280-005-0029-0
  31. Booth BP, Rahman A, Dagher R, Griebel D, Lennon S, Fuller D, Sahajwalla C, Mehta M, Gobburu JV. Population pharmacokinetic- based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol. 2007;47:101-111. https://doi.org/10.1177/0091270006295789
  32. Takama H, Tanaka H, Nakashima D, Ueda R, Takaue Y. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37:345-351. https://doi.org/10.1038/sj.bmt.1705252
  33. Sandstrom M, Karlsson MO, Ljungman P, Hassan Z, Jonsson EN, Nilsson C, Ringden O, Oberg G, Bekassy A, Hassan M. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplant. 2001;28:657-664. https://doi.org/10.1038/sj.bmt.1703229
  34. Schiltmeyer B, Klingebiel T, Schwab M, Mürdter TE, Ritter CA, Jenke A, Ehninger G, Gruhn B, Würthwein G, Boos J, Hempel G. Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol. 2003;52:209-216. https://doi.org/10.1007/s00280-003-0631-y
  35. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metabolism and Disposition. 2001;29:264-267.
  36. Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT. Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos. 1999;27:1466-1469.

Cited by

  1. Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation vol.101, pp.5, 2012, https://doi.org/10.1007/s12185-015-1756-6
  2. Antineoplastic busulfan encapsulated in a metal organic framework nanocarrier: first in vivo results vol.4, pp.4, 2016, https://doi.org/10.1039/c5tb02084k
  3. Therapeutic drug monitoring-guided dosing of busulfan differs from weight-based dosing in hematopoietic stem cell transplant patients vol.10, pp.2, 2012, https://doi.org/10.1016/j.hemonc.2017.03.003